RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

Core Viewpoint - RedHill Biopharma Ltd. has achieved a favorable summary judgment from the New York Supreme Court against Kukbo Co. Ltd, resulting in a total award exceeding $10.5 million, which is now eligible for enforcement and foreign recognition [1][2]. Financial Summary - The court awarded RedHill approximately $8.6 million as the main judgment, which is now final and enforceable [2]. - Additionally, RedHill was awarded approximately $1.9 million for legal fees and expenses, which remains subject to appeal until March 13, 2026 [2]. - A 9% annual statutory interest continues to accrue on both awards [2]. Legal Developments - RedHill has secured a court attachment in Korea against Kukbo to prevent asset disposal prior to the enforcement of the judgment [3]. Company Overview - RedHill Biopharma Ltd. focuses on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology [4]. - The company promotes the FDA-approved drug Talicia for treating Helicobacter pylori infection in adults, co-commercialized with Cumberland Pharmaceuticals [4]. - Key clinical programs include: - Opaganib, targeting multiple indications including COVID-19 and prostate cancer [4]. - RHB-204, aimed at Crohn's disease and pulmonary nontuberculous mycobacteria [4]. - RHB-107, in late-stage development for symptomatic COVID-19 and other diseases [4]. - RHB-102, with positive results for chemotherapy-induced nausea and vomiting [4].